TOKYO, Mar 25 (Pulse News Wire) – Kubota Pharmaceutical Holdings CO.,LTD. (4596.T) announced today that it has terminated its sales agreement with Sakata Pharmaceutical Co., Ltd.
Related to the product 'Kubota Glass®'. The agreement was originally signed on March 13, 2025, but due to unclear prospects for concrete orders from Sakata Pharma, Kubota decided to dissolve the relationship and focus on alternative distribution channels. Under the initial contract, Sakata Pharma was supposed to purchase approximately 600 units of 'Kubota Glass®' by August 2025. However, the Letter of Intent (LOI) supporting this agreement had already been canceled on September 3, 2025. As a result, Kubota has now officially ended all negotiations and transactions with Sakata Pharma effective March 25, 2026.
Regarding the manufacturing status and inventory handling associated with this contract, Kubota had ordered necessary long-term parts based on the assumption of fulfilling the agreement. These components remain in pre-assembled stock and were evaluated in the fiscal year ending December 2025, resulting in impairment losses being recognized. Sakata Pharmaceutical Co., Ltd., established on July 29, 2024, operates primarily in pharmaceuticals, health products, cosmetics, and various consulting services. It has a capital of ¥1 million and subsidiaries with additional capital contributions totaling ¥20.5 million and ¥60 million. Kubota stated that it will continue to assess the impact of this termination on its future performance.
🟢 Confidence: High AI-translated content.